Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer.

Monk BJ, Choi DC, Pugmire G, Burger RA

Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine, Medical Center, 101 The City Drive, Building 56, Room 262, Orange CA 92868, USA.

BACKGROUND: Angiogenesis is pivotal in the development and progression of ovarian cancer and is an ideal candidate for novel treatment approaches. CASE: A case of advanced, recurrent and refractory serous carcinoma is presented that responded to bevacizumab 15 mg/m2 intravenously every 3 weeks after failing eleventh line cytotoxic chemotherapy and radiation. An objective durable response lasting at least 5 months was documented. CONCLUSION: Bevacizumab has activity in epithelial ovarian carcinoma and larger scale trials are indicated.

Published 21 February 2005 in Gynecol Oncol, 96(3): 902-5.
Full-text of this article is available online (may require subscription).

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.